Belumosudil – a Rho-associated protein kinase-2 (ROCK2) inhibitor that reduces immune mediators like IL-17 and IL-23 – would be a first-in-class therapy for GVHD if approved by the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results